Meanwhile, a recent study demonstrated that FES activity was required for Flt3 function in acute myelogenous leukemia (AML), and in fact, dual inhibition of both Flt3 and FES might provide a therapeutic advantage for the treatment (Weir et al. 2017). This evidence concerns the gene FES and acute myeloid leukemia.